Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553278 | 0.87 | HSD17B3 (0.75) | HSD17B3KDM4EALDH1A1GAAHTT | |
| SCHEMBL10794925 | 0.87 | HSD17B3 (0.60) | HSD17B3KDM4ECSNK2A1PDE2AESR1 | |
| SCHEMBL10795110 | 0.86 | HSD17B3 (0.73) | HSD17B3KDM4ECSNK2A1PDE2AESR1 | |
| SCHEMBL10846673 | 0.84 | PDE2A (0.53) | HSD17B3KDM4EALDH1A1HTTCSNK2A1 | |
| SCHEMBL17861953 | 0.83 | NQO1 (0.51) | KDM4EALDH1A1GAAHTTCSNK2A1 | |
| SCHEMBL10602309 | 0.80 | NQO1 (0.49) | KDM4EALDH1A1GAAHTTCSNK2A1 | |
| SCHEMBL10792491 | 0.80 | HSD17B3 (0.77) | HSD17B3CSNK2A1PDE2AESR1ESR2 | |
| SCHEMBL10792497 | 0.80 | HSD17B3 (0.77) | HSD17B3KDM4EALDH1A1GAAHTT | |
| SCHEMBL5161656 | 0.79 | ERAP1 (0.59) | HSD17B3KDM4ECSNK2A1SMN1; SMN2LMNA | |
| SCHEMBL17838376 | 0.78 | ALDH1A1 (0.58) | KDM4EALDH1A1GAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| CN-107531722-B | Heterocyclic estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-10053451-B2 | Heterocyclic estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3303326-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| CN-107531722-A | Heterocyclic estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107406433-A | Derivatives of 2, 3-diphenylchromene for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-3233818-A1 | DERIVATIVES OF 2,3-DIPHENYLCHROMENE USEFUL FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016189011-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016097073-A1 | DERIVATIVES OF 2,3-DIPHENYLCHROMENE USEFUL FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-4618622-A | ANTIDEPRESSANTS, ANTIALLERGENS | BASF AKTIENGESELLSCHAFT (DE) | 1986-10-21 | — | — | US | disclosed |
| EP-0111746-A2 | Sulfonic-acid esters of hydroxycoumarines, their preparation and medicines containing them | BASF Aktiengesellschaft (DE) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053451-B2 | Heterocyclic estrogen receptor modulators and uses thereof | ESR2, GPER1, ESRRG | HSD17B3 102/4885KDM4E 2387/4885ALDH1A1 905/4885 |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | HSD17B3 75/4885KDM4E 2934/4885ALDH1A1 1132/4885 |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESRRG | HSD17B3 102/4885KDM4E 2387/4885ALDH1A1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.